
A recent study conducted in Vietnam and Indonesia investigated the effectiveness of adjunctive glucocorticoids in treating HIV-associated tuberculous meningitis. The double-blind, randomized, placebo-controlled trial involved 520 HIV-positive adults. Participants received either dexamethasone or a placebo alongside antituberculosis chemotherapy. The study found no significant difference in the 12-month survival rates between the groups of dexamethasone (44.1%) and placebo (49.0%). Subgroup analyses did not show clear benefits for dexamethasone. Additionally, both groups exhibited similar rates of serious adverse events. The study challenges the widespread use of glucocorticoids in this context, suggesting limited benefits in terms of survival or secondary endpoints.
Like
Save
Share